A real-world comparison study of drug survival of Tnf inhibitors and secukinumab in biologic naive patients with ankylosing spondylitis and psoriatic arthritis
Latest Information Update: 28 Jun 2020
At a glance
- Drugs Ixekizumab (Primary) ; Secukinumab (Primary) ; Tumour necrosis factor inhibitors (Primary)
- Indications Ankylosing spondylitis; Psoriatic arthritis
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 28 Jun 2020 New trial record
- 06 Jun 2020 Results presented at the 21st Annual Congress of the European League Against Rheumatism